RT Journal Article SR Electronic T1 Personalised medicine for nonsmall cell lung cancer JF European Respiratory Review JO EUROPEAN RESPIRATORY REVIEW FD European Respiratory Society SP 170066 DO 10.1183/16000617.0066-2017 VO 26 IS 146 A1 CĂ©line Mascaux A1 Pascale Tomasini A1 Laurent Greillier A1 Fabrice Barlesi YR 2017 UL http://err.ersjournals.com/content/26/146/170066.abstract AB After years of standard care prescribed to cancer patients without any selection except the primary site and histology of the tumour, the era of precision medicine has revolutionised cancer care. Personalised medicine refers to the selection of patients for specific treatment based on the presence of specific biomarkers which indicate sensitivity to corresponding targeted therapies and/or lower toxicity risk, such that patients will have the greatest chance of deriving benefit from the treatments. Here, we review personalised medicine for nonsmall cell lung cancer.Herein we review personalised medicine for nonsmall cell lung cancer http://ow.ly/LiiI30fXUlJ